How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are running two separate repair systems right now, and most people trying to support them are only thinking about one at a time.

The outer structure of a mitochondrion handles signaling and fusion, but the real work of energy production happens at the inner membrane, where a series of protein complexes called the electron transport chain pulls electrons down a gradient and uses that movement to build ATP. That process generates a byproduct, something called reactive oxygen species, which are unstable oxygen molecules that damage the very membrane they're produced in. Over time that damage compounds, the membrane loses its architecture, the protein complexes drift apart, and ATP output falls. That's the core of mitochondrial aging.

SS-31 and MOTS-c address that problem from completely different angles, which is why stacking them makes mechanistic sense, and also why the dosing logic for each one works nothing like the other.

Start with SS-31. The inner mitochondrial membrane is lined with a phospholipid called cardiolipin, which is what holds the electron transport chain complexes in the tight spatial arrangement they need to function. When cardiolipin oxidizes, those complexes drift, efficiency drops, and the membrane becomes leaky. SS-31 binds directly to cardiolipin and stabilizes it. It doesn't act on a receptor the way most drugs do. It binds to a structural lipid, which is why the PROGRESS-HF trial found that 40 milligrams per day showed no advantage over 4 milligrams in improving cardiac function. The compound concentrates roughly five thousand fold at the inner membrane, so even a small circulating amount arrives at the target in meaningful quantities.

The implication of that concentration effect is that you don't need a large dose. The working range in practice runs from 1 to 5 milligrams per day, with most people finding that 2 milligrams daily produces a measurable response without pushing into territory that adds cost without adding benefit.

SS-31 also has a half-life of about two hours, which means it clears the bloodstream quickly. That might sound like a reason to question daily dosing, but the mechanism explains why consistency matters more than peak concentration. The repair SS-31 enables at the cardiolipin level is structural and cumulative. It's not a signal that fades when the peptide does. Each day of dosing builds on what the previous day established, so the benefit accumulates over weeks, not hours. Daily administration maintains that steady-state presence at the membrane.

MOTS-c works through an entirely different system. It's a peptide that your mitochondria actually produce themselves, encoded in the mitochondrial genome rather than the nuclear genome, which makes it unusual among signaling molecules. At baseline your body makes it during metabolic stress, and its job is to act as a messenger that tells the rest of the cell what the mitochondria need. It activates something called the AMPK pathway, which is a cellular energy sensor that, when triggered, drives glucose uptake, improves insulin sensitivity, reduces fat accumulation, and stimulates mitochondrial quality control processes. A 2021 Nature Communications study showed that MOTS-c given three times per week after a daily loading phase maintained all the functional benefits, including physical performance and muscle homeostasis, that daily dosing had established.

That finding matters for how you build the protocol. MOTS-c doesn't work through steady plasma levels the way a drug targeting a plasma-measured outcome would. It triggers a gene expression cascade, and that cascade keeps running after the peptide is cleared. Three times per week is enough to keep the downstream signaling active. More frequent dosing during an initial loading phase can accelerate the onset of benefits, but maintenance doesn't require daily exposure.

So the dosing logic diverges sharply between the two compounds. SS-31 is daily because structural membrane repair requires continuous presence. MOTS-c is three times per week because gene expression cascades outlast the peptide itself. Running MOTS-c daily would be spending more to achieve the same outcome. Running SS-31 intermittently would leave gaps in the structural work it's doing.

The combined protocol most people work with is 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c spread across Monday, Wednesday, and Friday. That puts weekly MOTS-c exposure at 10 milligrams total, which sits in the middle of a 5 to 15 milligram weekly range derived from animal dosing data and early human extrapolation. If you're starting without prior peptide use, cutting both doses in half for the first few weeks lets you establish tolerance before moving to the standard range.

Now the cycling question, because this is where most protocols get the recommendation wrong for the wrong reasons.

The standard advice is 8 to 12 weeks on and 4 to 8 weeks off. That schedule comes from experience with hormonal compounds, where the receptor desensitization or feedback suppression that builds during a cycle genuinely requires time off to reverse. For SS-31 that logic doesn't apply. There is no receptor. The compound binds a structural lipid. There is nothing to desensitize. The longest available human trial ran SS-31 at 40 milligrams daily for 168 weeks continuously, and the data showed progressive improvement without tolerance development over that entire span. For MOTS-c, the mitochondria produce it endogenously, and unlike testosterone or growth hormone, there is no feedback axis that downregulates because you've been supplementing. Animal research has run it for the full lifespan of the subjects with sustained benefits.

The cycling recommendation survives because we genuinely don't have long-term human data at these doses for these purposes. That's an honest reason to be cautious. But the mechanism gives no signal that cycling is protective. It's a precaution against an unknown risk, not a response to a known one.

One thing worth being direct about: no human study has ever combined these two compounds and measured the outcome. The protocol is built from how each one works individually, from the absence of mechanistic overlap between them, and from the SS-31 plus NMN combination data in aged mice, which showed synergy between a membrane-targeting compound and a metabolic signaling compound, the closest published analogue to this stack. The evidence for combining them is rational inference, not a controlled trial.

That distinction matters because it changes what you're actually relying on when you run this protocol. You're not executing a tested combination. You're applying two well-characterized mechanisms in parallel because they address different parts of the same problem, and the science on each individually is solid enough to make that inference reasonable.

The gap between "this makes mechanistic sense" and "this has been tested as a combination" is exactly where most of the interesting work in mitochondrial medicine currently sits.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness